“The first thing you feel when a trial fails is a sense of shame,” says physician Siddhartha Mukherjee. Then comes the “exhilarating — and dangerous” instinct to slice and dice the data to resurrect the drug’s potential.
Here Siddartha discusses the lure to make more of the science than is perhaps there, when stakes are high and we are desperate to find hope for patients who are out of treatment options. Continue reading “When a clinical drug study fails…the importance of proper interpretation and dissemination of negative trial results”
Post contributed by Glenn Whiteside, Product Specialist for AdisInsight
I have a mate, let’s call him Steve, actually his name is Steve, and several years ago he noticed that the big toe on his right foot was turning black. Diagnosis revealed that he had poor circulation to his lower leg and foot because of venous occlusion caused years ago when he was stomped on in a rugby game. The long and short of it was that his toe needed to be amputated and a stent put into a vessel in his leg to fix the problem. Unfortunately for Steve and the three other guys in his room, they were all infected with MRSA (methicillin resistant Staphlococcus aureus). Steve ended up having two further amputations on his leg to try to stop the spreading infection. He tried every antibiotic in the arsenal, but none of them stopped the relentless progress of the infection, instead the bacteria just kept on eating his tissues. Steve was lucky in a way because he lived to tell his tale, albeit without the lower half of his leg. Continue reading “Antibiotic resistant superbugs – should we be worried?”
– Editors reinforce the critical role of patient involvement in decision-making around access to the medicines and health technologies they may need – Continue reading “The world’s first book dedicated to patient involvement in health technology assessment launched”
The recent first global approval of naldemedine has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Continue reading “Naldemedine (Symproic®): First Global Approval – new therapeutic option for sufferers of opioid-induced constipation”
The recent first global approval of telotristat ethyl has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Continue reading “Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome”